JAK inhibitors and infections risk: focus on herpes zoster

Sunzini, F., McInnes, I. and Siebert, S. (2020) JAK inhibitors and infections risk: focus on herpes zoster. Therapeutic Advances in Musculoskeletal Disease, 12, 1759720X20936059. (doi: 10.1177/1759720X20936059) (PMID:32655703) (PMCID:PMC7328488)

Abstract

Currently, there is a growing interest in Janus kinase (JAK) intracellular signalling since targeted inhibitors against these pathways are proving effective in the treatment of a range of immune-mediated diseases, such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease and atopic dermatitis. In particular, post marketing experience and the increasing development of new pharmacological inhibitors of broad and increasingly selective JAK pathways provide new insights into the JAK pathway role in viral infections as well as their pathogenic role in immune-mediated inflammatory diseases. Herein we provide an overview of the biological role of JAK signalling and its role in immunity against viruses, with particular regard to herpes zoster reactivation. Thereafter, we will discuss the evidence currently available on the principal JAK inhibitors and their association with viral infections.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: McInnes, Professor Iain and Sunzini, Miss Flavia and Siebert, Professor Stefan
• Authors: Sunzini, F., McInnes, I., and Siebert, S.
• College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
• Research Centre: College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
• Journal Name: Therapeutic Advances in Musculoskeletal Disease
• Publisher: SAGE Publications
• ISSN: 1759-720X
• ISSN (Online): 1759-7218
• Published Online: 29 June 2020
• Copyright Holders: Copyright © 2020 The Authors
• First Published: First published in Therapeutic Advances in Musculoskeletal Disease 12: 1759720X20936059
• Publisher Policy: Reproduced under a Creative Commons License